XmAb 5871

Drug Profile

XmAb 5871

Alternative Names: AMG 729; Anti-CD19 monoclonal antibody - Xencor; XmAb® 5871

Latest Information Update: 19 May 2017

Price : $50

At a glance

  • Originator Xencor
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; Fc gamma receptor IIB modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 11 May 2017 XmAb 5871 receives Orphan Drug status for Autoimmune disorders in USA
  • 09 May 2017 Adverse events data from a phase I trial in Healthy volunteers released by Xencor
  • 13 Nov 2016 Efficacy and adverse events data from the XmAb5871-03 phase II trial in Autoimmune disorders (IgG4-Related disease) released by Xencor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top